The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Defining Germline Sequencing and Incidental Germline Findings By Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, John Henson, MD, Augusta University, Ashley Ross, MD, PhD, Northwestern Medicine, Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.
EP. 2: Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling By Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, John Henson, MD, Augusta University, Ashley Ross, MD, PhD, Northwestern Medicine, Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.
EP. 3: Experience with Interpreting Somatic Reports By Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, John Henson, MD, Augusta University, Ashley Ross, MD, PhD, Northwestern Medicine, Dana Farengo Clark, MS, LCGC, Penn Medicine A panel of experts share their experiences with interpreting information on somatic reports and provide recommendations for verifying results.
EP. 4: Identification of Patients for Germline Testing By Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, John Henson, MD, Augusta University, Ashley Ross, MD, PhD, Northwestern Medicine, Dana Farengo Clark, MS, LCGC, Penn Medicine The panel of experts provide insight on how they identify patients for germline testing.
EP. 5: Role of ctDNA in Germline Testing By Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, John Henson, MD, Augusta University, Ashley Ross, MD, PhD, Northwestern Medicine, Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss the evolving role of circulating tumor DNA (ctDNA) in germline testing.
EP. 6: Operational Processes and Challenges By Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, John Henson, MD, Augusta University, Ashley Ross, MD, PhD, Northwestern Medicine, Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.